/
GLSI
$23.25+$3.45 (+17.42%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$290.6M
15M shares
52-week range
$7.78 – $34.10
59% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
104.23%
Hard to borrow
Price (6 mo)
Loading chart…
Change$-20.67
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $3.6K | $3.6K | $3.6K | $3.6K | $3.6K | $3.6K | $3.6K | $1.8K |
| Gross profit | −$3.6K | −$3.6K | −$3.6K | −$3.6K | −$3.6K | −$3.6K | −$3.6K | −$1.8K |
| Gross margin | — | — | — | — | — | — | — | — |
| R&D | $1.3M | $2.6M | $1.1M | $3.6M | $6.5M | $7.7M | $15.5M | $17.2M |
| Operating income | −$1.7M | −$3.4M | −$1.9M | −$4.6M | −$8.0M | −$9.3M | −$17.6M | −$19.4M |
| EBITDA | −$1.7M | −$3.4M | −$1.9M | −$4.6M | −$7.8M | −$8.9M | −$17.4M | −$19.4M |
| Net income | −$1.7M | −$3.4M | −$1.9M | −$4.6M | −$7.8M | −$8.9M | −$17.4M | −$19.4M |
| Net margin | — | — | — | — | — | — | — | — |
| EPS (diluted) | -0.14 | -0.29 | -0.15 | -0.35 | -0.61 | -0.69 | -1.21 | -1.43 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $0 | $-1.35 | $-1.48–$-1.22 | 1 |
| 2027 | $9M | $-1.47 | $-1.47–$-1.47 | 1 |
| 2028 | $140M | $3.98 | $3.98–$3.98 | 1 |
| 2029 | $311M | $9.90 | $9.90–$9.90 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$0.13
Price
$23.25
Implied downside
-99%
Peer comparison
Greenwich LifeSciences, Inc.
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9-amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75% of breast cancers.
www.greenwichlifesciences.com- Employees
- 13
- IPO / List date
- Sep 25, 2020
- HQ
- STAFFORD, TX
Held by traders on TradeandTell
No one on the platform currently holds GLSI.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2025-09-30 | 38,400 | $382.1K |
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2014-10-16 | 2-for-1 |
Recent trades on TradeandTell
No one on the platform has traded GLSI yet.
